Abstract W MP115: Patients With ICH Have Dynamic Electrocardiographic Changes Over Time

Background: Few studies have reported electrocardiographic (ECG) changes in patients with intracerebral hemorrhage (ICH). We performed a randomized controlled trial evaluating the safety of pioglitazone (PIO) versus placebo in patients with ICH (NCT00827892). Cardiac toxicity was evaluated with serial ECG. Methods: Patients enrolled into the Safety of Pioglitazone for Hematoma Resolution in ICH (SHRINC) trial were randomly allocated 1:1 to either placebo or PIO. Patients received escalating doses of PIO daily for 3 days (high-dose phase) beginning within 24 hours of symptom onset, followed by a 30mg maintenance dose for the duration of treatment. Serial ECGs were performed at baseline and on days 1, 2, 3 and 90. Zero inflated Poisson regression was used to model the relationship between treatment with PIO and the likelihood of observing new important ECG findings during the high-dose phase. Results: A total of 84 patients were enrolled in SHRINC (42 PIO, 42 placebo). At baseline, 60% of patients in both g...